Status:
UNKNOWN
Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients
Lead Sponsor:
Shandong University
Collaborating Sponsors:
The Second Hospital of Shandong University
Conditions:
Elderly Infection
Eligibility:
All Genders
65-100 years
Brief Summary
The investigator's purpose is to study the pharmacokinetics and pharmacodynamics of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients and recommend an...
Detailed Description
The use of biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc in elderly ICU patients during clinical treatment depended mostly on experience. Besides, there was no recommende...
Eligibility Criteria
Inclusion
- (1) Age ≥65 years old; (2) According to the doctor's advice, use biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc for anti-infection treatment;
Exclusion
- (1) Patients who are expected to die within 48 hours; (2) Patients with allergic to β-lactam antibiotics, Carbapenems, Ticacycline and Levofloxacin.etc drugs; (3) Patients receiving other investigational drugs; (4) Other factors that the researcher considers unsuitable for inclusion.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04799626
Start Date
April 1 2021
End Date
June 30 2023
Last Update
June 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wei Zhao
Jinan, Shandong, China